Successful immunomodulatory therapy in castleman disease with paraneoplastic pemphigus vulgaris.
Castleman disease is a rare lymphoproliferative disorder. The clinical signs and symptoms of the disease are primarily mediated by cytokines, especially interleukin-6. We presented the case of a young female. In May 2004, a 30-year-old otherwise healthy looking woman presented with oral ulcerations resistant to topical and systemic antibiotic and antimycotic treatment. Bullous mucosal lichen or pemphigus vulgaris were suspected. Histological examination and direct and indirect immunofluorescence confirmed the diagnosis of pemphigus. Search for neoplasm revealed a retroperitoneal Castleman tumour sized 15 x 6 x 5 cm in the abdominal MRI. The tumour was a bleeder, so the removal was partial. Histological examination showed hyalin hypervascular Castleman disease. Considering her young, fertile age and the multicentric Castleman disease, non-cytostatic immunomodulatory therapy was started including steroid, cyclosporine-A and thalidomide treatment. The control abdominal CT showed a small residual tumour on the bladder. The residual tumour was removed in repeated surgery. At this time the histological examination showed transient type tumour between plasma cell and vascular variant. Currently, i.e. 4 years after the onset of the disease. (18)FDG PET/CT examination showed low metabolic active mass in the right iliacal region, but our patient had no symptoms or complaints. She is on 200 mg thalidomide a day and no tumour progression can be seen. Castleman disease can be successfully treated with non-cytostatic immunomodulatory therapy.
Miltenyi
Zsofia
Z
3rd Department of Internal Medicine, Medical and Health Science Center, University of Debrecen, Debrecen, Hungary. mil03@freemail.hu
Toth
Judit
J
Gonda
Andrea
A
Tar
Ildiko
I
Remenyik
Eva
E
Illes
Arpad
A
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D005871:Castleman Disease / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D016572:Cyclosporine / Q000627:therapeutic use; D005260:Female; D006801:Humans; D056747:Immunomodulation; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D018365:Neoplasm, Residual / Q000188:drug therapy / Q000473:pathology; D010257:Paraneoplastic Syndromes / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D010392:Pemphigus / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D012186:Retroperitoneal Neoplasms / Q000150:complications / Q000188:drug therapy / Q000473:pathology; D013792:Thalidomide / Q000627:therapeutic use
D000305:Adrenal Cortex Hormones; D007166:Immunosuppressive Agents; D013792:Thalidomide; D016572:Cyclosporine